The strategic shift comes as investors scrutinize Novo’s ability to reclaim its leadership position in an obesity drug market projected to surpass $100 billion annually by 2030. While Novo pioneered the sector with the 2021 U.S. launch of Wegovy, it has lost significant momentum to Eli Lilly, which capitalized on the direct-to-consumer distribution of its Zepbound treatment.

Doustdar, who assumed leadership in August 2023, introduced a framework titled "The Novo Way," which includes a rebranding of the company's name and logo. The new corporate philosophy centers on four core principles: customer obsession, competitiveness, clarity, and a commitment to integrity. This internal push precedes a critical capital markets day scheduled for Monday, where management will face further evaluation from stakeholders regarding the company's long-term trajectory.